Share-based Compensation

3 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Incentive Plan

The Company has a stock incentive plan, the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”) that provides for the granting of stock options, restricted stock units (RSUs), performance stock options (PSOs) and other stock-based awards to eligible individuals on the terms and subject to the conditions set forth in the Plan. There have been no significant modifications to the Plan during the three months ended September 30, 2018 or 2017.

The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of comprehensive loss (in thousands):



	Three Months Ended
	September 30,
	2018		2017
Research and development	$	620	$	350
Sales and marketing	271		—
General and administrative	843		233
Total share-based compensation expense	$	1,734	$	583

The following table summarizes the activity for stock options, RSUs and PSOs for the three months ended September 30, 2018 (in thousands):



	Stock Options		RSUs		PSOs
Equity awards outstanding, beginning of year	3,549		1,535		538
Changes during the year:
Granted	1,279		15		—
Exercised	(219	)	(30	)	—
Expired or forfeited	(23	)	—		—
Equity awards outstanding, end of period	4,586		1,520		538

As of September 30, 2018, total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized were as follows ($ in thousands):



	Stock Options		RSUs		PSOs
Unrecognized compensation cost	$	25,959	$	405	$	3,228
Expected weighted-average period in years of compensation cost to be recognized	3.7		1.3		3.3